At a glance
ClinicalIndex Comparison RecordN/ACompleted· 169 enrolled
Drug / intervention
Evaluation of the evolution of biological markers from the biobank.other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Evaluation of the Evolution of Emerging Biological Markers (sST2, Copeptin, Chromogranin, NGAL, suPAR and Cystatin) in Patients Hospitalized for Acute Heart Failure (AHF) Depending on Their Management: Conventional or Therapeutic Adjustment According to Daily Ultrasound. Ancillary Study to the JECICA Study (AOI GCS MERRI 2015).
In Brief
An observational study evaluating Evaluation of the evolution of biological markers from the biobank. for Heart Failure. Completed, enrolled 169 participants across 2 sites.
Detailed Summary
This is a bi-centric, prospective randomized study to evaluate the contribution of rapid echocardioscopy at the patient's bedside to improving the prognosis of patients hospitalized for acute heart failure. The following markers will be evaluated: sST2, Copeptin, chromogranin, NGAL, suPAR and cystatin.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedMar 2022
Primary CompletionJul 2022
TodayJul 2026
First PostedMar 28, 2022
Enrollment StartFeb 15, 2022
Primary CompletionJul 9, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.3 years ago
Interventions
Evaluation of the evolution of biological markers from the biobank.other
The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1